Molecular downstaging: a new paradigm for neoadjuvant endocrine therapy.
作者信息
Ferraro Emanuela, Fornier Monica N
机构信息
Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Hematology and Hemato-Oncology, University of Milan, Milan, Italy.
出版信息
Ann Transl Med. 2020 Dec;8(24):1694. doi: 10.21037/atm-20-5406.
Abstract
摘要
相似文献
1
Molecular downstaging: a new paradigm for neoadjuvant endocrine therapy.分子降期：新辅助内分泌治疗的新模式。
Ann Transl Med. 2020 Dec;8(24):1694. doi: 10.21037/atm-20-5406.
2
Nodal downstaging as a treatment goal for node-positive pancreatic cancer.将淋巴结降期作为治疗目标治疗阳性胰腺癌。
Surgery. 2019 Jun;165(6):1144-1150. doi: 10.1016/j.surg.2018.12.009. Epub 2019 Feb 10.
3
Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma.食管癌术前化疗及根治性切除术后，T或N分期降低预示长期生存。
Ann Thorac Surg. 2006 Aug;82(2):480-4; discussion 484-5. doi: 10.1016/j.athoracsur.2006.03.072.
4
[Treatment Result of Neoadjuvant Endocrine Therapy in Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer in Our Hospital].[我院绝经后激素受体阳性乳腺癌患者新辅助内分泌治疗的疗效]
Gan To Kagaku Ryoho. 2020 Dec;47(13):2035-2037.
5
Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.新辅助内分泌治疗：患者选择、治疗持续时间及替代终点
Breast. 2015 Nov;24 Suppl 2:S78-83. doi: 10.1016/j.breast.2015.07.019. Epub 2015 Aug 6.
6
Neoadjuvant Endocrine Therapy: Who Benefits Most?新辅助内分泌治疗：谁获益最大？
Surg Oncol Clin N Am. 2018 Jan;27(1):121-140. doi: 10.1016/j.soc.2017.07.008.
7
[Downstaging correlates the prognosis of rectal cancer after intensified neoadjuvant chemoradiotherapy].[降期与强化新辅助放化疗后直肠癌的预后相关]
Zhonghua Wei Chang Wai Ke Za Zhi. 2014 Jun;17(6):547-50.
8
Evaluation for surrogacy of end points by using data from observational studies: tumor downstaging for evaluating neoadjuvant chemotherapy in invasive bladder cancer.利用观察性研究数据评估替代终点：用于评估浸润性膀胱癌新辅助化疗的肿瘤降期。
Clin Cancer Res. 2006 Jan 1;12(1):139-43. doi: 10.1158/1078-0432.CCR-05-1598.
9
Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States.在美国，新辅助内分泌治疗的应用、持续时间和结果。
Breast Cancer Res Treat. 2019 Nov;178(2):419-426. doi: 10.1007/s10549-019-05397-4. Epub 2019 Aug 10.
10
Radiological Downstaging with Neoadjuvant Therapy in Unresectable Gall Bladder Cancer Cases.新辅助治疗对不可切除胆囊癌病例进行放射学降期
Asian Pac J Cancer Prev. 2016;17(4):2137-40. doi: 10.7314/apjcp.2016.17.4.2137.
引用本文的文献
1
Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives.乳腺癌基因表达特征在临床实践中的应用：未解决的问题、正在进行的试验及未来展望
Cancers (Basel). 2021 Sep 28;13(19):4840. doi: 10.3390/cancers13194840.
本文引用的文献
1
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.新辅助化疗后病理完全缓解对乳腺癌复发和生存的影响：一项综合荟萃分析。
Clin Cancer Res. 2020 Jun 15;26(12):2838-2848. doi: 10.1158/1078-0432.CCR-19-3492. Epub 2020 Feb 11.
2
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.来曲唑联合瑞波西利对比化疗用于激素受体阳性、HER2 阴性、腔面 B 型乳腺癌的绝经后女性（CORALLEEN）：一项开放标签、多中心、随机、2 期临床试验。
Lancet Oncol. 2020 Jan;21(1):33-43. doi: 10.1016/S1470-2045(19)30786-7. Epub 2019 Dec 11.
3
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR/HER2 Breast Cancer.在 HR/HER2 乳腺癌的 neoMONARCH Ⅱ期新辅助研究中，阿贝西利联合来曲唑具有强大的细胞周期抑制作用，并上调免疫应答。
Clin Cancer Res. 2020 Feb 1;26(3):566-580. doi: 10.1158/1078-0432.CCR-19-1425. Epub 2019 Oct 15.
4
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.来曲唑联合 taselisib 与来曲唑联合安慰剂用于治疗绝经后雌激素受体阳性、HER2 阴性早期乳腺癌患者（LORELEI）：一项多中心、随机、双盲、安慰剂对照、Ⅱ期临床试验。
Lancet Oncol. 2019 Sep;20(9):1226-1238. doi: 10.1016/S1470-2045(19)30334-1. Epub 2019 Aug 8.
5
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.随机 II 期研究评估帕博西尼联合来曲唑作为雌激素受体阳性早期乳腺癌新辅助治疗：PALLET 试验。
J Clin Oncol. 2019 Jan 20;37(3):178-189. doi: 10.1200/JCO.18.01624. Epub 2018 Dec 6.
6
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.来曲唑联合帕博西利对比化疗用于高危型 luminal 乳腺癌的新辅助治疗。
Ann Oncol. 2018 Dec 1;29(12):2334-2340. doi: 10.1093/annonc/mdy448.
7
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.基于 21 基因表达检测的乳腺癌辅助化疗。
N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3.
8
Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict's value.新辅助帕博西利治疗 ER+ 乳腺癌（N007）：临床反应和 EndoPredict 的价值。
Endocr Relat Cancer. 2018 Feb;25(2):123-130. doi: 10.1530/ERC-17-0396. Epub 2017 Nov 20.
9
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.NeoPalAna研究：新辅助哌柏西利（一种细胞周期蛋白依赖性激酶4/6抑制剂）联合阿那曲唑治疗临床2期或3期雌激素受体阳性乳腺癌
Clin Cancer Res. 2017 Aug 1;23(15):4055-4065. doi: 10.1158/1078-0432.CCR-16-3206. Epub 2017 Mar 7.
10
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.70 基因特征作为早期乳腺癌治疗决策的辅助手段。
N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.
Zotero 插件